Replies to post #514238 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

And Dr. Liau reconfirmed PFS primary endpoint 14 years into the trial. Also selected PFS as the lead efficacy endpoint for her NCI SPORE Combination Keytruda immunotherapy trial too. But NWBO failed to meet the PFS primary endpoint and tossed it out.